[
  {
    "ts": null,
    "headline": "Down 93%, Is It Finally Time to Buy Moderna?",
    "summary": "As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top of mind back then.  A few years ago, Moderna (NASDAQ: MRNA) stock soared on the back of the highly successful vaccine it developed in record time.  At its peak in 2021, Moderna traded for over $450 per share.",
    "url": "https://finnhub.io/api/news?id=8b8d485b4460c9216131d408a14e67dddc06e9b12ef81b6d6ea02a3e5b51f3b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742027880,
      "headline": "Down 93%, Is It Finally Time to Buy Moderna?",
      "id": 133193256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top of mind back then.  A few years ago, Moderna (NASDAQ: MRNA) stock soared on the back of the highly successful vaccine it developed in record time.  At its peak in 2021, Moderna traded for over $450 per share.",
      "url": "https://finnhub.io/api/news?id=8b8d485b4460c9216131d408a14e67dddc06e9b12ef81b6d6ea02a3e5b51f3b2"
    }
  }
]